This trial is a randomized, blind, similar vaccine controlled, single center, non-inferiority design phase III clinical trial, with a study population of 10 to 60 years old, conducted in two stages.Phase 1 and Phase 2
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Antibody positive conversion rate - Immunogenicity endpoint
Timeframe: up to 14 days after the first/full dose of vaccination
Geometric mean concentration - Immunogenicity endpoint
Timeframe: 14 days after the first/full dose of vaccination
Incidence of Adverse Events [Safety and Tolerability]
Timeframe: within 30 minutes after each dose of vaccination
Incidence of Adverse Events [Safety and Tolerability]
Timeframe: within 0-7 days after each dose of vaccination
Incidence of Adverse Events [Safety and Tolerability]
Timeframe: within 30 days after the first dose of vaccination to the full course of vaccination
Incidence of Adverse Events [Safety and Tolerability]
Timeframe: within 6 months after the first dose administration and the entire vaccination process